Goldline Pharmaceutical Limited (BOM:544759)

Goldline Pharmaceutical Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 4, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Debt / Equity Ratio	1.07	1.07	1.42	1.84	1.50	1.45
Debt / EBITDA Ratio	1.80	1.80	2.56	4.49	6.05	6.45
Debt / FCF Ratio	5.22	5.22	6.14	8.44	-	-
Net Debt / Equity Ratio	0.95	0.95	1.32	1.83	1.48	1.44
Net Debt / EBITDA Ratio	1.59	1.59	2.38	4.46	5.97	6.38
Net Debt / FCF Ratio	4.63	4.63	5.70	8.40	-	-
Asset Turnover	1.14	1.14	1.11	1.00	1.20	-
Inventory Turnover	1.52	1.52	0.95	1.08	2.67	-
Quick Ratio	1.01	1.01	1.02	0.97	1.18	1.00
Current Ratio	1.99	1.99	1.92	1.87	2.37	2.01
Return on Equity (ROE)	31.11%	31.11%	26.26%	4.01%	4.86%	-
Return on Assets (ROA)	14.98%	14.98%	12.35%	7.06%	5.17%	-
Return on Invested Capital (ROIC)	22.59%	22.59%	17.14%	8.49%	7.26%	6.58%
Return on Capital Employed (ROCE)	40.60%	40.60%	32.80%	21.50%	12.90%	13.10%
Payout Ratio	7.58%	7.58%	12.00%	84.49%	-	-
Buyback Yield / Dilution	-14.54%	-14.95%	-0.04%	-0.09%	0.49%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jun 5, 2026

Data Sources Report a data error